Search research articles
Contact Us
Filters
Showing results (91-100 of 115) with videos related to
Page
of 12
Sort By:
Haematologica
|
October 19, 2023
Outcomes of limited stage primary bone diffuse large B-cell lymphoma in the rituximab era: a multicenter, retrospective study
Alexandra Rezazadeh, Aniko Szabo, Arushi Khurana, et al.
Transplantation and Cellular Therapy
|
April 14, 2022
Targeted Marrow Irradiation Intensification of Reduced-Intensity Fludarabine/Busulfan Conditioning for Allogeneic Hematopoietic Stem Cell Transplantation
Naveed Ali, Ashish Arunkumar Sharma, Ana Carolina Pires de Rezende, et al.
Nature Communications
|
December 11, 2021
Multiple site place-of-care manufactured anti-CD19 CAR-T cells induce high remission rates in B-cell malignancy patients
Michael Maschan, Paolo F Caimi, Jane Reese-Koc, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation
|
December 12, 2017
Efficacy of High-Dose Therapy and Autologous Hematopoietic Cell Transplantation in Gray Zone Lymphoma: A US Multicenter Collaborative Study
Mohamed A Kharfan-Dabaja, Renju Raj, Liana Nikolaenko, et al.
Blood
|
September 22, 2023
Tafasitamab and lenalidomide in large B-cell lymphoma: real-world outcomes in a multicenter retrospective study
David A Qualls, Nicholas Lambert, Paolo F Caimi, et al.
Hemasphere
|
November 20, 2025
Outcomes of tafasitamab and lenalidomide in large B-cell lymphoma based on prior CD19-directed CAR T exposure
Mwanasha H Merrill, Robert A Redd, Nicholas Lambert, et al.
Blood Advances
|
August 30, 2024
Evaluation of prognostic factors in patients with high-risk classical Hodgkin lymphoma undergoing autologous transplantation
Narendranath Epperla, Ying Huang, Amanda F Cashen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 8, 2021
Umbralisib, a Dual PI3Kδ/CK1ε Inhibitor in Patients With Relapsed or Refractory Indolent Lymphoma
Nathan H Fowler, Felipe Samaniego, Wojciech Jurczak, et al.
American Journal of Hematology
|
June 6, 2015
Gray zone lymphoma with features intermediate between classical Hodgkin lymphoma and diffuse large B-cell lymphoma: characteristics, outcomes, and prognostication among a large multicenter cohort
Andrew M Evens, Jennifer A Kanakry, Laurie H Sehn, et al.
Blood
|
May 31, 2024
Randomized study of induction with bendamustine-rituximab ± bortezomib and maintenance with rituximab ± lenalidomide for MCL
Mitchell R Smith, Opeyemi A Jegede, Peter Martin, et al.
Page
of 12
Search research articles
Search
Showing results (91-100 of 115) with videos related to
Sort By:
Page
of 12
Haematologica
|
October 19, 2023
Outcomes of limited stage primary bone diffuse large B-cell lymphoma in the rituximab era: a multicenter, retrospective study
Alexandra Rezazadeh, Aniko Szabo, Arushi Khurana, et al.
Transplantation and Cellular Therapy
|
April 14, 2022
Targeted Marrow Irradiation Intensification of Reduced-Intensity Fludarabine/Busulfan Conditioning for Allogeneic Hematopoietic Stem Cell Transplantation
Naveed Ali, Ashish Arunkumar Sharma, Ana Carolina Pires de Rezende, et al.
Nature Communications
|
December 11, 2021
Multiple site place-of-care manufactured anti-CD19 CAR-T cells induce high remission rates in B-cell malignancy patients
Michael Maschan, Paolo F Caimi, Jane Reese-Koc, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation
|
December 12, 2017
Efficacy of High-Dose Therapy and Autologous Hematopoietic Cell Transplantation in Gray Zone Lymphoma: A US Multicenter Collaborative Study
Mohamed A Kharfan-Dabaja, Renju Raj, Liana Nikolaenko, et al.
Blood
|
September 22, 2023
Tafasitamab and lenalidomide in large B-cell lymphoma: real-world outcomes in a multicenter retrospective study
David A Qualls, Nicholas Lambert, Paolo F Caimi, et al.
Hemasphere
|
November 20, 2025
Outcomes of tafasitamab and lenalidomide in large B-cell lymphoma based on prior CD19-directed CAR T exposure
Mwanasha H Merrill, Robert A Redd, Nicholas Lambert, et al.
Blood Advances
|
August 30, 2024
Evaluation of prognostic factors in patients with high-risk classical Hodgkin lymphoma undergoing autologous transplantation
Narendranath Epperla, Ying Huang, Amanda F Cashen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 8, 2021
Umbralisib, a Dual PI3Kδ/CK1ε Inhibitor in Patients With Relapsed or Refractory Indolent Lymphoma
Nathan H Fowler, Felipe Samaniego, Wojciech Jurczak, et al.
American Journal of Hematology
|
June 6, 2015
Gray zone lymphoma with features intermediate between classical Hodgkin lymphoma and diffuse large B-cell lymphoma: characteristics, outcomes, and prognostication among a large multicenter cohort
Andrew M Evens, Jennifer A Kanakry, Laurie H Sehn, et al.
Blood
|
May 31, 2024
Randomized study of induction with bendamustine-rituximab ± bortezomib and maintenance with rituximab ± lenalidomide for MCL
Mitchell R Smith, Opeyemi A Jegede, Peter Martin, et al.
Page
of 12